Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Mechanism of increase in plasma intact GLP-1 by metformin in type 2 diabetes: stimulation of GLP-1 secretion or reduction in plasma DPP-4 activity?

Literature DB >> 25172519

Mechanism of increase in plasma intact GLP-1 by metformin in type 2 diabetes: stimulation of GLP-1 secretion or reduction in plasma DPP-4 activity?

Tongzhi Wu¹, Sony S Thazhath¹, Michelle J Bound¹, Karen L Jones¹, Michael Horowitz¹, Christopher K Rayner².

Abstract

Metformin was reported to increase plasma intact glucagon-like peptide-1 (GLP-1) concentrations in type 2 diabetes. This is, at least partly, attributable to stimulation of GLP-1 secretion. A reduction in soluble dipeptidyl peptidase-4 activity may also make a modest contribution.

Entities: Chemical Disease Gene

Keywords: Dipeptidyl peptidase-4; Enteral nutrition; Glucagon-like peptide-1; Metformin

Mesh：

Substances：

Year: 2014 PMID： 25172519 DOI： 10.1016/j.diabres.2014.08.004

Source DB: PubMed Journal: Diabetes Res Clin Pract ISSN： 0168-8227 Impact factor: 5.602

Keyword Cloud
Cited

28 in total

1. Metformin-induced glucagon-like peptide-1 secretion contributes to the actions of metformin in type 2 diabetes.

Authors: Emilie Bahne; Emily W L Sun; Richard L Young; Morten Hansen; David P Sonne; Jakob S Hansen; Ulrich Rohde; Alice P Liou; Margaret L Jackson; Dayan de Fontgalland; Philippa Rabbitt; Paul Hollington; Luigi Sposato; Steven Due; David A Wattchow; Jens F Rehfeld; Jens J Holst; Damien J Keating; Tina Vilsbøll; Filip K Knop
Journal: JCI Insight Date: 2018-12-06

2. Prediction of the effect on antihyperglycaemic action of sitagliptin by plasma active form glucagon-like peptide-1.

Authors: Akifumi Kushiyama; Takako Kikuchi; Kentaro Tanaka; Tazu Tahara; Toshiko Takao; Yukiko Onishi; Yoko Yoshida; Shoji Kawazu; Yasuhiko Iwamoto
Journal: World J Diabetes Date: 2016-06-11

3. Comparison of area under the curve in various models of diabetic rats receiving chronic medication.

Authors: Keng-Fan Liu; Chiang-Shan Niu; Jen-Chieh Tsai; Chao-Lin Yang; Wen-Huang Peng; Ho-Shan Niu
Journal: Arch Med Sci Date: 2020-01-07 Impact factor: 3.707

4. Metabolic consequences of acute and chronic empagliflozin administration in treatment-naive and metformin pretreated patients with type 2 diabetes.

Authors: Elza Muscelli; Brenno Astiarraga; Elisabetta Barsotti; Andrea Mari; Freimut Schliess; Leszek Nosek; Tim Heise; Uli C Broedl; Hans-Juergen Woerle; Ele Ferrannini
Journal: Diabetologia Date: 2015-12-24 Impact factor: 10.122

5. Sustained influence of metformin therapy on circulating glucagon-like peptide-1 levels in individuals with and without type 2 diabetes.

Authors: David Preiss; Adem Dawed; Paul Welsh; Alison Heggie; Angus G Jones; Jacqueline Dekker; Robert Koivula; Tue H Hansen; Caitlin Stewart; Rury R Holman; Paul W Franks; Mark Walker; Ewan R Pearson; Naveed Sattar
Journal: Diabetes Obes Metab Date: 2016-12-28 Impact factor: 6.577

Mechanism of increase in plasma intact GLP-1 by metformin in type 2 diabetes: stimulation of GLP-1 secretion or reduction in plasma DPP-4 activity?

1. Metformin-induced glucagon-like peptide-1 secretion contributes to the actions of metformin in type 2 diabetes.

2. Prediction of the effect on antihyperglycaemic action of sitagliptin by plasma active form glucagon-like peptide-1.

3. Comparison of area under the curve in various models of diabetic rats receiving chronic medication.

4. Metabolic consequences of acute and chronic empagliflozin administration in treatment-naive and metformin pretreated patients with type 2 diabetes.

5. Sustained influence of metformin therapy on circulating glucagon-like peptide-1 levels in individuals with and without type 2 diabetes.

Review 6. Therapeutic Use of Metformin in Prediabetes and Diabetes Prevention.

Review 7. Metformin and the gastrointestinal tract.

8. Plasma DPP4 activity is associated with no-reflow and major bleeding events in Chinese PCI-treated STEMI patients.

9. Elevated circulating fasting glucagon-like peptide-1 in surgical patients with aortic valve disease and diabetes.

Review 10. Multiple Factors Related to the Secretion of Glucagon-Like Peptide-1.